Dr. Patrick J. Ward, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 371
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Ohio State University College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35075469 · KY license 38228
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bethesda North Cincinnati, OH
- The Jewish Hospital-Mercy Health Cincinnati, OH
- Mercy Health-Anderson Hospital Cincinnati, OH
- Mercy Health - Clermont Hospital Batavia, OH
- Mercy Health Kings Mills Hospital LLC Mason, OH
Medical groups
- Oncology Hematology Care Inc (63 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 371
- Services billed
- 120,828
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 16,204 | 14 |
| Injection, nivolumab, 1 mg | 13,660 | 11 |
| Injection, denosumab, 1 mg | 3,540 | 15 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,360 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,064 | 49 |
| Injection, palonosetron hcl, 25 mcg | 1,550 | 29 |
| Injection, ferric derisomaltose, 10 mg | 1,300 | 11 |
| Injection, leucovorin calcium, per 50 mg | 1,006 | 13 |
| Injection, granisetron hydrochloride, 100 mcg | 950 | 22 |
| Injection, fluorouracil, 500 mg | 715 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Cincinnati, OH | 298 |
| Verzenio (abemaciclib) | 60 |
| Dexamethasone Other prescribers in Cincinnati, OH | 59 |
| Imbruvica (ibrutinib) | 54 |
| Anastrozole Other prescribers in Cincinnati, OH | 47 |
| Hydroxyurea Other prescribers in Cincinnati, OH | 47 |
| Potassium Chloride Other prescribers in Cincinnati, OH | 42 |
| Olanzapine Other prescribers in Cincinnati, OH | 42 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 40 |
| Tagrisso (osimertinib mesylate) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 37 payments worth $5,946 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,010 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $1,110 |
| Avyxa Pharma, LLC | $1,000 |
| AbbVie Inc. | $176 |
| Janssen Biotech, Inc. | $115 |
| Genentech USA, Inc. | $107 |
| Novartis Pharmaceuticals Corporation | $94.91 |
| Aveo Pharmaceuticals, Inc. | $84.80 |
| Consulting Fee | $4,120 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,000 |
| Food and Beverage | $619 |
| Education | $207 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 18, 2025 | Consulting Fee | $3,010 |
| AstraZeneca Pharmaceuticals LP Jan 1, 2025 | Consulting Fee | $1,110 |
| Avyxa Pharma, LLC Dec 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,000 |
| Janssen Biotech, Inc. Dec 12, 2025 | Education ERLEADA · Oncology · in-kind | $99.99 |
| Genentech USA, Inc. Jun 17, 2025 | Education in-kind | $53.45 |
| Genentech USA, Inc. Jun 17, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 26 industry-funded studies in 2025, from 13 companies. The companies reported $869,346 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated K…
Amgen Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Amgen Inc. - Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
E.r. Squibb & Sons, L.l.c. - A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo Inc. · Recruiting · NCT06203210 - A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
AstraZeneca Pharmaceuticals LP - Pan Tumor Rollover Study
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT03899155 - A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company · Recruiting · NCT06119581 - Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie Inc. · Active, not recruiting · NCT06236438 - My Pathway
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.